Biogen
NEWS
Investors love to speculate on M&A, and one of the hottest topics of speculation recently has been whether someone will buy BMS.
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results.
ALZ’s researchers continue to see hope in Biogen’s aducanumab.
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year.
Despite the failures of late stage ALZ’s drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.
JOBS
IN THE PRESS